APP and Alzheimer disease: In this regard, the effects of triple GLP-1/GIP/glucagon receptor agonists in the APP/PS1 transgenic AD mouse model reduced the total amounts of β-amyloid, neuroinflammation and oxidative stress in the cortex and hippocampus (215).